journal article·2020-01-01Open access

The enhanced treatment efficacy of invasive brain glioma by dual-targeted artemether plus paclitaxel micelles

Xiuying Li, Luanxia Shi, Yandong Li, Qinqing Li, Xiujun Duan, Yingli Wang, Qingshan Li

Abstract

High grade-gliomas are highly invasive and prone to metastasis, leading to poor survival and prognosis. Currently, we urgently need a new treatment strategy to effectively inhibit glioma. In this study, artemether and paclitaxel were used as two agents for tumour suppression. Two functional materials were synthesised and modified on the surface of the micelle as targeting molecules. The addition of two functional materials confers the ability of the micelles to effectively cross the blood-brain barrier (BBB) and then target the glioma cells. Thus, this dual-targeted delivery system allows the drug to play a better role in inhibiting tumour invasion and vasculogenic mimicry (VM) channels. In this paper, the anticancer effects of dual-targeted artemether plus paclitaxel micelles on glioma U87 cells were studied in three aspects: (I) In vitro and in vivo targeting assessment, including the role of penetrating BBB and targeting glioma; (II) In vitro regulation of invasion-associated proteins; (III) Inhibition of VM channels formation and invasion in vitro; (IV) The study of pharmacodynamics in tumour-bearing mice. These results suggest that dual-targeted artemether plus paclitaxel micelle may provide a new strategy to treat glioma via inhibiting invasive and VM channels.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Glioma Diagnosis and Treatment · Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Research Center for Engineering (Technology) of Traditional Chinese Medicine Microemulsions and New Biological Preparations, Shanxi University of Chinese Medicine

Shanxi Key Laboratory of Innovative Drug for the Treatment of Serious Diseases Basing on the Chronic Inflammation, Shanxi University of Chinese Medicine

Department of Pathology, The First Affilated Hospital of Xi’an Medical University

Funding

Research Centre for Engineering (Technology) of Traditional Chinese Medicine Microemulsions · New Biological Preparations, Shanxi University of Chinese Medicine · Shanxi Province Science Foundation for Youths · National Natural Science Foundation of China · Scientific Research Fund of Shanxi Administration of Traditional Chinese Medicine · Scientific and Technological Innovation Ability Cultivation Project of Shanxi University of Chinese Medicine · Shanxi Education Science · Special Research Project

References (41)

Show source-provided references
1. 10.1038/nature2401410.1038/nature24014 ↗
2. 10.1586/14737159.2014.90520210.1586/14737159.2014.905202 ↗
3. 10.1016/j.rcl.2019.06.00410.1016/j.rcl.2019.06.004 ↗
4. 10.1126/sciadv.150135410.1126/sciadv.1501354 ↗
5. 10.1016/j.ccell.2018.04.00410.1016/j.ccell.2018.04.004 ↗
6. 10.1021/acsnano.7b0696910.1021/acsnano.7b06969 ↗
7. 10.1039/C8CS00805A10.1039/C8CS00805A ↗
8. 10.1038/ncomms519610.1038/ncomms5196 ↗
9. 10.1016/j.biomaterials.2014.03.04910.1016/j.biomaterials.2014.03.049 ↗
10. 10.1021/acsami.5b0993410.1021/acsami.5b09934 ↗
11. 10.1021/acsami.5b0459610.1021/acsami.5b04596 ↗
12. 10.1021/nn504210g10.1021/nn504210g ↗
13. 10.1016/j.addr.2017.02.00310.1016/j.addr.2017.02.003 ↗
14. 10.1016/j.semcancer.2017.02.00910.1016/j.semcancer.2017.02.009 ↗
15. 10.1182/blood-2016-03-70538410.1182/blood-2016-03-705384 ↗
16. 10.1038/nature1490910.1038/nature14909 ↗
17. 10.1080/21691401.2018.144697110.1080/21691401.2018.1446971 ↗
18. 10.1080/21691401.2018.148108210.1080/21691401.2018.1481082 ↗
19. 10.1080/08982104.2017.140864910.1080/08982104.2017.1408649 ↗
20. 10.1080/21691401.2019.161593210.1080/21691401.2019.1615932 ↗
21. 10.1200/JCO.2003.05.06310.1200/JCO.2003.05.063 ↗
22. 10.1016/j.drup.2015.02.00210.1016/j.drup.2015.02.002 ↗
23. 10.1007/s00401-018-1815-110.1007/s00401-018-1815-1 ↗
24. 10.1016/j.stem.2017.10.00210.1016/j.stem.2017.10.002 ↗
25. 10.1038/ni.354510.1038/ni.3545 ↗
26. 10.1038/s41467-019-09397-210.1038/s41467-019-09397-2 ↗
27. 10.1038/ncb359610.1038/ncb3596 ↗
28. 10.1016/j.molcel.2017.07.01410.1016/j.molcel.2017.07.014 ↗
29. 10.1080/21691401.2019.164828210.1080/21691401.2019.1648282 ↗
30. 10.1007/s00401-013-1101-110.1007/s00401-013-1101-1 ↗
31. 10.1038/ncomms1232910.1038/ncomms12329 ↗
32. 10.1038/s41568-018-0038-z10.1038/s41568-018-0038-z ↗
33. 10.1038/ncb333010.1038/ncb3330 ↗
34. 10.1038/ncomms1034710.1038/ncomms10347 ↗
35. 10.1016/j.ccr.2008.01.03410.1016/j.ccr.2008.01.034 ↗
36. 10.1002/ijc.2766610.1002/ijc.27666 ↗
37. 10.1016/j.biomaterials.2014.03.07710.1016/j.biomaterials.2014.03.077 ↗
38. 10.1093/annonc/mdx29310.1093/annonc/mdx293 ↗
39. 10.1139/bcb-2018-007310.1139/bcb-2018-0073 ↗
40. 10.1158/2159-8290.CD-18-117510.1158/2159-8290.CD-18-1175 ↗
41. 10.1007/s00401-018-1864-510.1007/s00401-018-1864-5 ↗